165 related articles for article (PubMed ID: 26338418)
1. A common polymorphism in the 5' UTR of ERCC5 creates an upstream ORF that confers resistance to platinum-based chemotherapy.
Somers J; Wilson LA; Kilday JP; Horvilleur E; Cannell IG; Pöyry TA; Cobbold LC; Kondrashov A; Knight JR; Puget S; Grill J; Grundy RG; Bushell M; Willis AE
Genes Dev; 2015 Sep; 29(18):1891-6. PubMed ID: 26338418
[TBL] [Abstract][Full Text] [Related]
2. The 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs.
Rulli E; Guffanti F; Caiola E; Ganzinelli M; Damia G; Garassino MC; Piva S; Ceppi L; Broggini M; Marabese M
Sci Rep; 2016 Dec; 6():39217. PubMed ID: 27966655
[TBL] [Abstract][Full Text] [Related]
3. MZF1 possesses a repressively regulatory function in ERCC1 expression.
Yan QW; Reed E; Zhong XS; Thornton K; Guo Y; Yu JJ
Biochem Pharmacol; 2006 Mar; 71(6):761-71. PubMed ID: 16426580
[TBL] [Abstract][Full Text] [Related]
4. Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer.
He C; Duan Z; Li P; Xu Q; Yuan Y
Anticancer Drugs; 2013 Mar; 24(3):300-5. PubMed ID: 23211354
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of the nucleotide excision repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells.
Sabatino MA; Marabese M; Ganzinelli M; Caiola E; Geroni C; Broggini M
Mol Cancer; 2010 Sep; 9():259. PubMed ID: 20868484
[TBL] [Abstract][Full Text] [Related]
6. [Effect of XPG down-regulation gene expression towards the proliferation of epithelial ovarian cancer cells and its chemosensitivity to platinum].
Zhang W; Wu FX; Wang Q; Li L
Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):286-91. PubMed ID: 22781116
[TBL] [Abstract][Full Text] [Related]
7. Role of DNA repair gene polymorphisms in the efficiency of platinum-based adjuvant chemotherapy for non-small cell lung cancer.
Mathiaux J; Le Morvan V; Pulido M; Jougon J; Bégueret H; Robert J
Mol Diagn Ther; 2011 Jun; 15(3):159-66. PubMed ID: 21766907
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms of XPG/ERCC5 and risk of squamous cell carcinoma of the head and neck.
Ma H; Yu H; Liu Z; Wang LE; Sturgis EM; Wei Q
Pharmacogenet Genomics; 2012 Jan; 22(1):50-7. PubMed ID: 22108238
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of upstream open reading frames (uORF) in the 5' untranslated regions (UTR) of genes in Saccharomyces cerevisiae.
Zhang Z; Dietrich FS
Curr Genet; 2005 Aug; 48(2):77-87. PubMed ID: 16012843
[TBL] [Abstract][Full Text] [Related]
11. ERCC5 is a novel biomarker of ovarian cancer prognosis.
Walsh CS; Ogawa S; Karahashi H; Scoles DR; Pavelka JC; Tran H; Miller CW; Kawamata N; Ginther C; Dering J; Sanada M; Nannya Y; Slamon DJ; Koeffler HP; Karlan BY
J Clin Oncol; 2008 Jun; 26(18):2952-8. PubMed ID: 18565881
[TBL] [Abstract][Full Text] [Related]
12. ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer.
Chen J; Xie F; Chen K; Wang D; Jiang H; Li J; Pan F; Chen S; Zhang Y; Ruan Z; Huang H; Zou L; Liang H
Cancer Biol Ther; 2009 Jul; 8(14):1424-30. PubMed ID: 19458483
[TBL] [Abstract][Full Text] [Related]
13. The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity.
Gao R; Reece K; Sissung T; Reed E; Price DK; Figg WD
Mutat Res; 2011 Mar; 708(1-2):21-7. PubMed ID: 21315089
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
Kudo K; Gavin E; Das S; Amable L; Shevde LA; Reed E
Oncogene; 2012 Nov; 31(44):4718-24. PubMed ID: 22266871
[TBL] [Abstract][Full Text] [Related]
15. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
Olaussen KA; Mountzios G; Soria JC
Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174
[TBL] [Abstract][Full Text] [Related]
16. Role of XRCC1 and ERCC5 polymorphisms on clinical outcomes in advanced non-small cell lung cancer.
Liu D; Wu J; Shi GY; Zhou HF; Yu Y
Genet Mol Res; 2014 Apr; 13(2):3100-7. PubMed ID: 24782167
[TBL] [Abstract][Full Text] [Related]
17. miR‑138‑5p modulates the expression of excision repair cross‑complementing proteins ERCC1 and ERCC4, and regulates the sensitivity of gastric cancer cells to cisplatin.
Ning J; Jiao Y; Xie X; Deng X; Zhang Y; Yang Y; Zhao C; Wang H; Gu K
Oncol Rep; 2019 Feb; 41(2):1131-1139. PubMed ID: 30535472
[TBL] [Abstract][Full Text] [Related]
18. Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.
Powrózek T; Kowalski DM; Krawczyk P; Ramlau R; Kucharczyk T; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Dyszkiewicz W; Krzakowski M; Milanowski J
Clin Lung Cancer; 2014 Nov; 15(6):455-65. PubMed ID: 25246386
[TBL] [Abstract][Full Text] [Related]
19. CITED2 silencing sensitizes cancer cells to cisplatin by inhibiting p53 trans-activation and chromatin relaxation on the ERCC1 DNA repair gene.
Liu YC; Chang PY; Chao CC
Nucleic Acids Res; 2015 Dec; 43(22):10760-81. PubMed ID: 26384430
[TBL] [Abstract][Full Text] [Related]
20. Effects of β-glucan extracted from Agaricus blazei on the expression of ERCC5, CASP9, and CYP1A1 genes and metabolic profile in HepG2 cells.
da Silva AF; Sartori D; Macedo FC; Ribeiro LR; Fungaro MH; Mantovani MS
Hum Exp Toxicol; 2013 Jun; 32(6):647-54. PubMed ID: 23424205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
